
Sean Mcgarry
Examiner (ID: 8444, Phone: (571)272-0761 , Office: P/1674 )
| Most Active Art Unit | 1635 |
| Art Unit(s) | 1635, 1809, 1624, 1674, 1621, 1805 |
| Total Applications | 1928 |
| Issued Applications | 1074 |
| Pending Applications | 340 |
| Abandoned Applications | 559 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17393524
[patent_doc_number] => 11242527
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2022-02-08
[patent_title] => Combination vectors and methods for treating cancer
[patent_app_type] => utility
[patent_app_number] => 17/198017
[patent_app_country] => US
[patent_app_date] => 2021-03-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 19
[patent_no_of_words] => 19370
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 87
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17198017
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/198017 | Combination vectors and methods for treating cancer | Mar 9, 2021 | Issued |
Array
(
[id] => 17082390
[patent_doc_number] => 20210277396
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-09
[patent_title] => METHODS AND COMPOSITIONS FOR SENSITIZATION OF TUMOR CELLS TO IMMUNE THERAPY
[patent_app_type] => utility
[patent_app_number] => 17/191466
[patent_app_country] => US
[patent_app_date] => 2021-03-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38685
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -43
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17191466
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/191466 | Methods and compositions for sensitization of tumor cells to immune therapy | Mar 2, 2021 | Issued |
Array
(
[id] => 16961637
[patent_doc_number] => 20210213136
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-15
[patent_title] => TARGETING PAX2 FOR THE TREATMENT OF BREAST CANCER
[patent_app_type] => utility
[patent_app_number] => 17/189525
[patent_app_country] => US
[patent_app_date] => 2021-03-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27591
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17189525
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/189525 | Targeting PAX2 for the treatment of breast cancer | Mar 1, 2021 | Issued |
Array
(
[id] => 18391717
[patent_doc_number] => 20230159935
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-25
[patent_title] => CIRCULAR BIFUNCTIONAL APTAMERS AND TRIFUNCTIONAL APTAMERS TARGETING Tau
[patent_app_type] => utility
[patent_app_number] => 17/797217
[patent_app_country] => US
[patent_app_date] => 2021-03-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26709
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17797217
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/797217 | CIRCULAR BIFUNCTIONAL APTAMERS AND TRIFUNCTIONAL APTAMERS TARGETING Tau | Feb 28, 2021 | Pending |
Array
(
[id] => 17067582
[patent_doc_number] => 20210269797
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-02
[patent_title] => METHODS AND COMPOSITIONS FOR TARGETING PD-L1
[patent_app_type] => utility
[patent_app_number] => 17/249335
[patent_app_country] => US
[patent_app_date] => 2021-02-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15448
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17249335
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/249335 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | Feb 25, 2021 | Abandoned |
Array
(
[id] => 19855742
[patent_doc_number] => 12258566
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-03-25
[patent_title] => Oligonucleotides for PRNP modulation
[patent_app_type] => utility
[patent_app_number] => 17/187129
[patent_app_country] => US
[patent_app_date] => 2021-02-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 45429
[patent_no_of_claims] => 50
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 98
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17187129
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/187129 | Oligonucleotides for PRNP modulation | Feb 25, 2021 | Issued |
Array
(
[id] => 16877989
[patent_doc_number] => 11028122
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2021-06-08
[patent_title] => Antisense nucleic acids
[patent_app_type] => utility
[patent_app_number] => 17/175276
[patent_app_country] => US
[patent_app_date] => 2021-02-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 19
[patent_figures_cnt] => 19
[patent_no_of_words] => 16785
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 59
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17175276
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/175276 | Antisense nucleic acids | Feb 11, 2021 | Issued |
Array
(
[id] => 17082393
[patent_doc_number] => 20210277399
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-09
[patent_title] => Methods of Imaging and Tracking Nucleic Acids in Cells
[patent_app_type] => utility
[patent_app_number] => 17/172480
[patent_app_country] => US
[patent_app_date] => 2021-02-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8864
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 7
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17172480
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/172480 | Methods of Imaging and Tracking Nucleic Acids in Cells | Feb 9, 2021 | Abandoned |
Array
(
[id] => 17312959
[patent_doc_number] => 20210402007
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-30
[patent_title] => POLYNUCLEOTIDE AGENTS TARGETING HYDROXYACID OXIDASE (GLYCOLATE OXIDASE, HAO1) AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/166063
[patent_app_country] => US
[patent_app_date] => 2021-02-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 49401
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17166063
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/166063 | POLYNUCLEOTIDE AGENTS TARGETING HYDROXYACID OXIDASE (GLYCOLATE OXIDASE, HAO1) AND METHODS OF USE THEREOF | Feb 2, 2021 | Abandoned |
Array
(
[id] => 20115023
[patent_doc_number] => 12364707
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-07-22
[patent_title] => Manipulation of eIF3 to modulate repeat associated non-ATG (RAN) translation
[patent_app_type] => utility
[patent_app_number] => 17/159288
[patent_app_country] => US
[patent_app_date] => 2021-01-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 38
[patent_no_of_words] => 6781
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 72
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17159288
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/159288 | Manipulation of eIF3 to modulate repeat associated non-ATG (RAN) translation | Jan 26, 2021 | Issued |
Array
(
[id] => 18504855
[patent_doc_number] => 11702660
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-07-18
[patent_title] => Modulation of gene expression and screening for deregulated protein expression
[patent_app_type] => utility
[patent_app_number] => 17/159881
[patent_app_country] => US
[patent_app_date] => 2021-01-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 31
[patent_figures_cnt] => 69
[patent_no_of_words] => 37902
[patent_no_of_claims] => 47
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 86
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17159881
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/159881 | Modulation of gene expression and screening for deregulated protein expression | Jan 26, 2021 | Issued |
Array
(
[id] => 20115023
[patent_doc_number] => 12364707
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-07-22
[patent_title] => Manipulation of eIF3 to modulate repeat associated non-ATG (RAN) translation
[patent_app_type] => utility
[patent_app_number] => 17/159288
[patent_app_country] => US
[patent_app_date] => 2021-01-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 38
[patent_no_of_words] => 6781
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 72
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17159288
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/159288 | Manipulation of eIF3 to modulate repeat associated non-ATG (RAN) translation | Jan 26, 2021 | Issued |
Array
(
[id] => 17119830
[patent_doc_number] => 11130953
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-09-28
[patent_title] => Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 17/158375
[patent_app_country] => US
[patent_app_date] => 2021-01-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 12
[patent_no_of_words] => 54066
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 112
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17158375
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/158375 | Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof | Jan 25, 2021 | Issued |
Array
(
[id] => 17198728
[patent_doc_number] => 20210338822
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-04
[patent_title] => THERAPEUTIC EXOSOMES AND METHOD OF PRODUCING THEM
[patent_app_type] => utility
[patent_app_number] => 17/156512
[patent_app_country] => US
[patent_app_date] => 2021-01-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9035
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -30
[patent_words_short_claim] => 14
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17156512
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/156512 | THERAPEUTIC EXOSOMES AND METHOD OF PRODUCING THEM | Jan 21, 2021 | Abandoned |
Array
(
[id] => 19242179
[patent_doc_number] => 12012601
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-06-18
[patent_title] => Combination therapy with liposomal antisense oligonucleotides
[patent_app_type] => utility
[patent_app_number] => 17/150151
[patent_app_country] => US
[patent_app_date] => 2021-01-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 17
[patent_no_of_words] => 30294
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 55
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17150151
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/150151 | Combination therapy with liposomal antisense oligonucleotides | Jan 14, 2021 | Issued |
Array
(
[id] => 19027481
[patent_doc_number] => 11926828
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-03-12
[patent_title] => Methods for treating aging and skin disorders using nucleic acids targeting TYR or MMP1
[patent_app_type] => utility
[patent_app_number] => 17/150614
[patent_app_country] => US
[patent_app_date] => 2021-01-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 14
[patent_no_of_words] => 42507
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 159
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17150614
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/150614 | Methods for treating aging and skin disorders using nucleic acids targeting TYR or MMP1 | Jan 14, 2021 | Issued |
Array
(
[id] => 18230356
[patent_doc_number] => 20230069350
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-02
[patent_title] => METHODS AND COMPOSITIONS RELATING TO PROLONGED INFLAMMATORY INHIBITION AND/OR PROLONGED TREATMENT OF SPINAL PAIN BY CHIMERA DECOY
[patent_app_type] => utility
[patent_app_number] => 17/793377
[patent_app_country] => US
[patent_app_date] => 2021-01-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18023
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17793377
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/793377 | METHODS AND COMPOSITIONS RELATING TO PROLONGED INFLAMMATORY INHIBITION AND/OR PROLONGED TREATMENT OF SPINAL PAIN BY CHIMERA DECOY | Jan 13, 2021 | Pending |
Array
(
[id] => 19505164
[patent_doc_number] => 12116576
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-10-15
[patent_title] => Oligonucleotides for modulating SCN9A expression
[patent_app_type] => utility
[patent_app_number] => 17/130451
[patent_app_country] => US
[patent_app_date] => 2020-12-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37245
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 128
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17130451
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/130451 | Oligonucleotides for modulating SCN9A expression | Dec 21, 2020 | Issued |
Array
(
[id] => 16900743
[patent_doc_number] => 20210179659
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-17
[patent_title] => ANTISENSE NUCLEIC ACIDS
[patent_app_type] => utility
[patent_app_number] => 17/126366
[patent_app_country] => US
[patent_app_date] => 2020-12-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16573
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 225
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17126366
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/126366 | ANTISENSE NUCLEIC ACIDS | Dec 17, 2020 | Abandoned |
Array
(
[id] => 16916293
[patent_doc_number] => 20210189385
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-24
[patent_title] => CLOSED LOOP CONTINUOUS APTAMER DEVELOPMENT SYSTEM
[patent_app_type] => utility
[patent_app_number] => 17/126842
[patent_app_country] => US
[patent_app_date] => 2020-12-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10313
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 130
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17126842
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/126842 | Closed loop continuous aptamer development system | Dec 17, 2020 | Issued |